奇正藏药：公司目前没有直接从美国进口的原材料

Core Viewpoint - The company has stated that it does not directly import raw materials from the United States, and changes in U.S. policies will not affect its production costs [1] Group 1 - The company's foreign business revenue accounted for only 0.05% of total revenue in the first half of 2025, indicating that policy changes will have a minimal impact on its income [1] - Overall risk is considered manageable for the company [1]